Armstrong Advisory Group’s BridgeBio Pharma BBIO Stock Holding History

Armstrong Advisory Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$198	Buy	+3	New	+$234	﹤0.01%	1021

Other funds holding BBIO

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Planning Strategies Lancaster, Pennsylvania $169M AUM

Armstrong Advisory Group's BBIO Position: Q3 2026 in Review

Armstrong Advisory Group opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 3 shares worth $198. The stake represents ﹤0.01% of the portfolio and ranks #1021 among its holdings.

12 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

Armstrong Advisory Group held 3 shares of BridgeBio Pharma worth $198 as of Q3 2026.
BridgeBio Pharma was a new Armstrong Advisory Group position in Q3 2026.
BridgeBio Pharma made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #1021 holding.
12 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.